These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27657985)

  • 21. Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men.
    Hashimoto Y; Kamioka T; Hosaka M; Mabuchi K; Mizuchi A; Shimazaki Y; Tsunoo M; Tanaka T
    J Clin Endocrinol Metab; 2000 Feb; 85(2):601-6. PubMed ID: 10690862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human growth hormone-binding protein fails to enhance the in vivo bioactivity of human growth hormone in normal rats.
    Tzanela M; Wagner C; Tannenbaum GS
    Endocrinology; 1997 Dec; 138(12):5316-24. PubMed ID: 9389516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys.
    Ashkenazi N; Rosenstock M; Hallak H; Bassan M; Rasamoelisolo M; Leuschner J; Shinar D
    Growth Horm IGF Res; 2016; 30-31():16-21. PubMed ID: 27552669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study.
    Takács I; Jókai E; Kováts DE; Aradi I
    Osteoporos Int; 2019 Mar; 30(3):675-683. PubMed ID: 30357438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IGF-I/IGFBP-1 as an index for discrimination between responder and nonresponder to recombinant human growth hormone in malnourished uremic patients on hemodialysis.
    Shinobe M; Sanaka T; Nihei H; Sugino N
    Nephron; 1997; 77(1):29-36. PubMed ID: 9380235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children.
    Ferry RJ; Cohen P; Levitt Katz LE
    Horm Res; 2005; 63(5):220-7. PubMed ID: 15886488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle.
    Brearley C; Priestley A; Leighton-Scott J; Christen M
    BMC Clin Pharmacol; 2007 Oct; 7():10. PubMed ID: 17922895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients.
    Garibotto G; Barreca A; Russo R; Sofia A; Araghi P; Cesarone A; Malaspina M; Fiorini F; Minuto F; Tizianello A
    J Clin Invest; 1997 Jan; 99(1):97-105. PubMed ID: 9011582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L; Chen ZH; Liu D; Cheng YG; Luo XP
    Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic effects of 20-kilodalton human growth hormone (20K-hGH) for adults with growth hormone deficiency: results of an exploratory uncontrolled multicenter clinical trial of 20K-hGH.
    Hayakawa M; Shimazaki Y; Tsushima T; Kato Y; Takano K; Chihara K; Shimatsu A; Irie M
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1562-71. PubMed ID: 15070913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open-Label, Randomized, Two-Way, Crossover Study Assessing the Bioequivalence of the Liquid Formulation versus the Freeze-Dried Formulation of Recombinant Human FSH and Recombinant Human LH in a Fixed 2:1 Combination (Pergoveris
    Bagchus W; Yalkinoglu Ö; Wolna P
    Front Endocrinol (Lausanne); 2017; 8():371. PubMed ID: 29375477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV-1106, a Long-Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects.
    Cohen-Barak O; Barkay H; Rasamoelisolo M; Butler K; Yamada K; Bassan M; Yoon E; Spiegelstein O
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):331-342. PubMed ID: 27489211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles.
    Kim SJ; Hahn SK; Kim MJ; Kim DH; Lee YP
    J Control Release; 2005 May; 104(2):323-35. PubMed ID: 15907583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
    Thygesen P; Andersen HS; Behrens C; Fels JJ; Nørskov-Lauritsen L; Rischel C; Johansen NL
    Growth Horm IGF Res; 2017 Aug; 35():8-16. PubMed ID: 28595133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of various doses of biosynthetic growth hormone on levels of IGF-I binding protein 3 (IGFBP-3) in patients with hypopituitarism and growth hormone deficiency].
    Justová V; Lacinová Z; Marek J
    Sb Lek; 2002; 103(2):133-9. PubMed ID: 12688134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate.
    Hahn SK; Kim SJ; Kim MJ; Kim DH
    Pharm Res; 2004 Aug; 21(8):1374-81. PubMed ID: 15359571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin.
    Fuhr U; Tuculanu D; Berghout A; Balser S; Schwebig A; Saenger P
    Eur J Endocrinol; 2010 Jun; 162(6):1051-8. PubMed ID: 20332125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles.
    Wei Y; Wang Y; Kang A; Wang W; Ho SV; Gao J; Ma G; Su Z
    Mol Pharm; 2012 Jul; 9(7):2039-48. PubMed ID: 22663348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioequivalence of Genotropin and Somatonorm.
    Wilton P; Widlund L; Guilbaud O
    Acta Paediatr Scand Suppl; 1987; 337():118-21. PubMed ID: 3481177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.